Lv1
90 积分 2023-06-22 加入
Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma
1个月前
已关闭
A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma
1个月前
已关闭
The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO + IPI) in patients (pts) with uveal melanoma (UM)
1个月前
已关闭
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)
1个月前
已完结
Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
1个月前
已完结
Advances in immunotherapy for uveal melanoma: enhancing efficacy and overcoming resistance
1个月前
已关闭
Nanotechnology in Uveal Melanoma: Cutting-Edge Advances to Halt Progression and Metastasis
1个月前
已完结
Uveal Melanoma Treatment: An Update
1个月前
已完结
皖公网安备34019202002308
